CABA Cabaletta Bio, Inc.
Cabaletta Bio, Inc. (CABA) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: January 21, 2026 , by Simon Mark .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Nichtberger Steven | President & CEO | Buy | 45,000 | $2.24 | $100.8K | 1,031,483 | |
| Tomasello Shawn | Director | Buy | 22,725 | $2.21 | $50.3K | 22,725 | |
| Gavel Steve | Chief Commercial Officer | Buy | 22,170 | $2.27 | $50.2K | 22,170 | |
| Simon Mark | Director | Buy | 11,061 | $2.28 | $25.3K | 147,205 | |
| Binder Gwendolyn | President, Science & Tech. | Buy | 11,312 | $2.19 | $24.8K | 31,312 | |
| Chang David J. | Chief Medical Officer | Buy | 8,800 | $2.26 | $19.9K | 8,800 | |
| Gerard Michael | General Counsel | Buy | 6,600 | $2.27 | $15.0K | 6,600 | |
| Bollard Catherine | Director | Buy | 4,405 | $2.27 | $10.0K | 5,405 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.